Authors:

J. L�ke¹, Z. Madarasz², A. Schad³, S. Schrewe¹, W. Roth³, W. Hiller², T. Hansen¹

Institut f�r Pathologie, Klinikum Lippe

Abstract:

1.1. Objective: Pancreatic ductal adenocarcinoma (PDAC) accounts for up to 95% of all malignant pancreatic neoplasms and constitutes the most frequent histopathologic entity among pancreatic neoplasms. Prognosis is mainly dependent on the stage of disease at diagnosis and overall outcomes are poor. KRAS-mutants are frequently observed in PDAC. There is, however, a percentage of PDAC cases with wild-type KRAS. ROS1 is a tyrosine kinase that has been recognized as a promising therapeutic target, when rearranged. Rearrangements have rarely been reported to be present in malignancies of the pancreato-biliary system, such as cholangiocarcinoma.

Keywords:

ROS1 fusions, pancreatic ductal, adenocarcinomas

Citation:

J.Luke. ROS1 fusions are absent in a series of 109 pancreatic ductal adenocarcinomas. World Journal of Clinical Surgery 2020.